Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting

Table 3

Diagnosis and median sIL-2R level per group.

Diagnosis	Total patients per group	Median sIL-2R pg/ml (Q3-Q1)
Healthy controls	101	1515.0 (1880.0-1150.0)
CRPS group	23	2809.0 (3913.0-1589.0)
No CRPS group	29	3654.0 (4429.0-2095.5)
Neuropathic pain syndromes^1 (, % no CRPS group)	7 (24.1)	4170.0 (5203.0-2050.0)
Myofascial pain syndromes^2 (, % no CRPS group)	17 (58.6)	3529.0 (4253.5-2150.5)
Inflammation^3 (, % no CRPS group)	2 (6.9)	N/A
Unknown^4 (, % no CRPS group)	3 (10.3)	N/A

¹Neuropathic pain syndromes: peripheral neuropathy (); cervical dermatomal pain (); radicular pain (). ²Myofascial pain syndromes: postfracture pain and osteoarthritis (); osteoarthritis (); disuse (); myalgia (); disability and impairment of hand related to fracture as diagnosed by plastic surgeon (); shin splints (); subacromial pain syndrome (); unspecified pain of the shin (); suspected patellofemoral pain syndrome (); suspected clenched fist syndrome (); pain related to healing process after trauma (); postsurgical pain (). ³Inflammation: osteomyelitis (); arthritis of the wrist (). Median sIL-2R levels were not calculated due to the size of the group. ⁴Median sIL-2R levels were not calculated due to the size of the group.